de.mpg.escidoc.pubman.appbase.FacesBean
English
 
Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Animal models with pathological mineralization phenotypes

MPS-Authors
http://pubman.mpdl.mpg.de/cone/persons/resource/persons50391

Kornak,  U.
Research Group Development & Disease (Head: Stefan Mundlos), Max Planck Institute for Molecular Genetics, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Kornak, U. (2011). Animal models with pathological mineralization phenotypes. Joint Bone Spine, 78(6), 561-7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21550285 http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272233&_user=28761&_pii=S1297319X11000789&_check=y&_origin=article&_zone=toolbar&_coverDate=31-Dec-2011&view=c&originContentFamily=serial&wchp=dGLzVBA-zSkzS&md5=418f55f8cdf675985ad1603de5bdfe9d/1-s2.0-S1297319X11000789-main.pdf.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0010-77FE-D
Abstract
Extracellular matrix mineralization is important for mechanical stability of the skeleton and for calcium and phosphate storage. Professional mineral-disposing cell types are hypertrophic chondrocytes, odontoblasts, ameloblasts and osteoblasts. Since ectopic mineralization causes tissue dysfunction mineralization inhibitors and promoting factors have to be kept in close balance. The most prominent inhibitors are fetuin-A, matrix-Gla-protein (MGP), SIGBLING proteins and pyrophosphate. In spite of their ubiquitous presence, their loss entails a specific rather than a stereotypic pattern of ectopic mineralization. Typical sites of pathological mineral accumulation are connective tissues, articular cartilage, and vessels. Associated common human pathologies are degenerative joint disorders and arteriosclerosis. This article gives a summary on what we have learned from different mouse models with pathologic mineralization phenotypes about the role of these inhibitors and the regulation of mineralization promoting factors.